Immunohistochemistry (IHC) analysis demonstrated hormone receptor positivity, with the tumor being Estrogen Receptor-positive (ER+) and Progesterone Receptor-positive (PR+) but Human Epidermal Growth Factor Receptor 2-negative (HER2-). The gene discussed is ESR1; the disease is neoplasm.